• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Medicus Pharma Ltd. - Common Stock (NQ:MDCX)

    0.3203 -0.0280 (-8.04%)
    Streaming Delayed Price Updated: 1:15 PM EDT, Jun 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Medicus Pharma Ltd. - Common Stock

    < Previous 1 2 3 4 Next >
    News headline image
    New to The Street Broadcasts Nationwide on Bloomberg Television Featuring "Opportunities To Consider(TM)" Across Artificial Intelligence, Healthcare Innovation, Fintech, Digital Assets, and Commodities
    Via ACCESS Newswire
    News headline image
    Medicus Pharma Announces $22 Million Non-Dilutive Financing
    Financing Provides Immediate Growth Capital to Support Clinical Development Initiatives and Extends Projected Operating Cash Runway for Over Two (2) Years 
    From Medicus Pharma Ltd
    Via GlobeNewswire
    News headline image
    Alzheimer’s AI Biotech IGC Pharma, Inc. (NYSE: IGC) Stock in Focus – More Stocks Inside
    Via AB Newswire
    Topics Artificial Intelligence Intellectual Property
    News headline image
    New to The Street Broadcasts Episode 753 Today at 6:30 PM EST Across Bloomberg Television U.S., MENA, and Latin America Featuring Leaders in VR Defense Training, AI Streaming, Healthcare Innovation, and Global Workforce Technology
    Via ACCESS Newswire
    News headline image
    New to The Street's Show #753 Airs Nationwide on Bloomberg Television Across the U.S., MENA and Latin America Featuring FreeCast (NASDAQ:CAST), Stardust Power (NASDAQ:SDST), Lost Soldier Oil and Gas, Virtuix Holdings (NASDAQ:VTIX), and Medicus Pharma
    Via ACCESS Newswire
    News headline image
    Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
    Company Advances SkinJect® and Teverelix® Clinical Programs While Strengthening Financing Flexibility and Expanding Strategic Development Initiatives 
    From Medicus Pharma Ltd
    Via GlobeNewswire
    News headline image
    New to The Street Broadcasts Show #752 on Bloomberg Television Featuring Graphene Manufacturing Group (OTCQX:GMGRF), T-REX Acquisition Corp (NASDAQ:TRXA), KITON, and Roadzen (NASDAQ:RDZN)
    Via ACCESS Newswire
    News headline image
    Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response
    200µg Cohort Achieves 55% Complete Response at Day 57 Emerging as Registrational Grade Lead Regimen 
    From Medicus Pharma Ltd
    Via GlobeNewswire
    News headline image
    GLOBAL MARKETS SPOTLIGHT: New to The Street Show #748 Delivers High-Impact CEO Interviews and Spotlight TV Commercials Across Bloomberg to 250M+ Households Worldwide
    Via ACCESS Newswire
    News headline image
    Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill
    Builds Support for Accelerated Access to SkinJect® for Gorlin Syndrome patients with a Rare Autosomal Dominant Disease 
    From Medicus Pharma Ltd
    Via GlobeNewswire
    News headline image
    New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO Global
    Via ACCESS Newswire
    News headline image
    New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM EST - Show #744 Featuring Virtuix Holdings (NASDAQ:VTIX), Neonc Technologies Holdings (NASDAQ:NTHI), Medicus Pharma (NASDAQ:MDCX), YY Group Holding (NASDAQ:YYGH), and Vivos Therapeutics
    Via ACCESS Newswire
    News headline image
    Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome
    Targets rare, high-burden genetic condition with no approved therapies; advances non-surgical treatment strategy for recurrent basal cell carcinoma 
    From Medicus Pharma Ltd
    Via GlobeNewswire
    News headline image
    Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression
    Updated Safety, Efficacy, and Clinical Data Supports Teverelix as Potentially the First Long-Acting Injectable GnRH Antagonist Across Multiple Indications in Women’s Health 
    From Medicus Pharma Ltd
    Via GlobeNewswire
    News headline image
    New to The Street to Broadcast on Fox Business on Monday, April 13, Featuring Virtuix Holdings (NASDAQ:VTIX), Medicus Pharma (NASDAQ:MDCX), YY Group Holdings (NASDAQ:YYGH), Vivos Therapeutics (NASDAQ:VVOS), and Stardust Power (NASDAQ:SDST)
    Via ACCESS Newswire
    News headline image
    New to The Street Signs Medicus Pharma Ltd. (NASDAQ:MDCX) to Transformational 12-Part National Media Series Highlighting SkinJect(TM) and Teverelix(R) Platforms
    Via ACCESS Newswire
    News headline image
    Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention
    Mechanism-Driven Study Design Focused on Capital Efficiency and Accelerated Development for Near-Term Value Creation, Addressing a $2 Billion Potential Target Market 
    From Medicus Pharma Ltd
    Via GlobeNewswire
    News headline image
    Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset
    Provides guidance on interpretation of Topline dataset and confirms focus on drug-driven efficacy in non-melanoma skin cancer 
    From Medicus Pharma Ltd
    Via GlobeNewswire
    News headline image
    Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate
    Dr. Babar Rao highlights clinically meaningful outcomes with majority of lesions potentially avoiding immediate surgery in non-melanoma Skin Cancer 
    From Medicus Pharma Ltd
    Via GlobeNewswire
    Medicus Pharma (MDCX): A Small-Cap Biotech Making Moves in 2026
    Via AB Newswire
    News headline image
    Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan
    200µg Cohort at Day 57 Dataset suggests majority of treated Lesions may Avoid Surgery as Company targets larger unmet medical need in Non-melanoma Skin Cancer 
    From Medicus Pharma Ltd
    Via GlobeNewswire
    News headline image
    Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update
    Via ACCESS Newswire
    News headline image
    Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst
    Via ACCESS Newswire
    News headline image
    Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26
    From Medicus Pharma Ltd
    Via GlobeNewswire
    News headline image
    New to The Street Episode #737 Airs on Bloomberg Television Across the United States, Latin America, and MENA at 6:30 PM EST
    Via ACCESS Newswire
    News headline image
    Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum
    Via ACCESS Newswire
    News headline image
    American Lithium Minerals (OTC: AMLM) Targets Tokenized Commodities Opportunity Alongside MDCX, ASNS, EONR, ELPW Today!
    Via AB Newswire
    Topics Artificial Intelligence
    News headline image
    Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset
    The Company Reported 73% Clinical Clearance in the 200-µg cohort at Day 57 
    From Medicus Pharma Ltd
    Via GlobeNewswire
    News headline image
    New to The Street Broadcasts Tonight on Bloomberg Television at 6:30 PM EST - Shows 736, 737 and 738 Air Across the U.S., Latin America and MENA
    Via ACCESS Newswire
    News headline image
    Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort
    The Company is expected to finalize the Clinical Study Report (CSR) in Q2 2026 to support planned end of Phase 2 (EOP2) meeting with the FDA 
    From Medicus Pharma Ltd
    Via GlobeNewswire
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.